Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DTaP-IPV combined vaccine · 1 trial · 4 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DTaP-IPV combined vaccine | BIOLOGICAL | 0.5 mL, IM |
| DTaP vaccine | BIOLOGICAL | 0.5 mL, IM |
Inclusion Criteria: * Aged 56 to 70 days inclusive on the day of inclusion * Born at full term pregnancy (\>37 weeks) with a birth weight ≥ 2.5 kg * Informed consent form signed by the parent(s) or other legal representative * Able to attend all scheduled visits and to comply with all trial procedu...
DTaP-IPV combined vaccine is used for the prevention of pertussis, diphtheria, poliomyelitis, and tetanus. It is a combination vaccine that provides protection against these infectious diseases. The vaccine is being developed for use in infants and young children, as the clinical trial enrolled participants as young as 56 days old.
DTaP-IPV combined vaccine is being developed by Sanofi, a multinational pharmaceutical company. Sanofi is listed on the stock exchange under the ticker symbol SNY. The company is conducting clinical trials to evaluate the vaccine's immunogenicity and safety for the prevention of pertussis and other infectious diseases.
DTaP-IPV combined vaccine is currently in Phase 3 clinical development. It is an investigational vaccine, meaning it has not yet been approved by regulatory authorities. The Phase 3 trial has been completed, and the vaccine is being evaluated for its safety and ability to generate an immune response against pertussis, diphtheria, poliomyelitis, and tetanus.
DTaP-IPV combined vaccine has one completed Phase 3 clinical trial registered under NCT00319852. The trial, titled "Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV," enrolled 442 participants in South Korea. The study was active-controlled and evaluated the vaccine's immunogenicity and safety in healthy volunteers.
DTaP-IPV combined vaccine works by stimulating the immune system to produce antibodies against the bacteria and viruses that cause pertussis, diphtheria, tetanus, and poliomyelitis. It is a combination vaccine that includes components for diphtheria, tetanus, acellular pertussis, and inactivated poliovirus, providing broad protection against these diseases.
Yes, DTaP-IPV combined vaccine is also known as Tetraxim. The clinical trial NCT00319852 compared Tetraxim against a local DTP + IPV vaccine. This combination vaccine is designed to protect against diphtheria, tetanus, pertussis, and poliomyelitis in a single formulation.